The Peptide CommonsEst. May 2024
Independent. We sell nothing and are affiliated with no manufacturer or pharmacy. Every moderation action is logged in public
Evidence · Study critique

A structured critique template this community uses

ZO
z.okonkwoTL2 Moderator15 Jul 2026#1

A structured critique template this community uses — setting out what I have, and where I think it stops being reliable.

Comparing SURMOUNT-2 (Lancet, 2023) with SURPASS-4 (Lancet, 2021) and finding the comparison harder than it looks.

Different populations, different durations, different endpoints defined slightly differently, and in one case a different estimand. People compare the headline percentages anyway, including me until recently.

Is there a defensible way to put these side by side, or is the honest answer that there is not and we should stop?

7 likes 13d
C
chromatogramTL4Analytical chemist22 Jul 2026#2

Generalisability: do the inclusion/exclusion criteria narrow the population so much that results do not apply to real people asking about it? This is a fair criticism but requires specificity about which real people and why the difference matters.

0 likes 6d
EK
e.kuuselaTL2 Moderator27 Jul 2026#3

Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own records is not any individual result; it is that they are dated and consecutive.

32 likes 1d

Suggested topics

TopicParticipantsRepliesViewsActivity
A claim built entirely on a subgroup analysis — what changed since
On the subject in the title: A claim built entirely on a subgroup analysis — what changed since Working notes rather than a conclusion. I have seen PIONEER 6 ( N Engl J Med , 2019) cited in support of a claim…
AWZCQZ 2 2k 18mo
Critiquing an observational claim about a class effect
Posting this under the heading it deserves: Critiquing an observational claim about a class effect Everything below is what sits behind that. Session topic: SCALE ( N Engl J Med , 2015). Please read it before…
VRRIJV 2 6.9k 14mo
About the Study critique category
Structured criticism of a specific published study. Criticise the method, not the author. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is recorded with its…
BNJNDEHF 4 114 16mo
Criticising the method without criticising the authors
Criticising the method without criticising the authors Writing it up because I had to work it out twice and would rather nobody else did. I have seen STEP 1 ( N Engl J Med , 2021) cited in support of a claim…
KBZOKOJMTV+55 61 60k 15mo
Measurement error in a self-reported exposure
Posting this under the heading it deserves: Measurement error in a self-reported exposure Everything below is what sits behind that. Session topic: SURPASS-2 ( N Engl J Med , 2021). Please read it before…
LHCKSVCW+117 129 45k 5mo

Related topics — sharing the tags observational data, effect size, risk of bias

TopicParticipantsRepliesViewsActivity
[2026 update] What we do not know about retatrutide, listed explicitly
What we do not know about retatrutide, listed explicitly — that is the question, and I have not found it answered plainly anywhere I have looked. Comparing SCALE ( N Engl J Med , 2015) with STEP 2 ( Lancet ,…
FWCFATKCKB+79 83 952 11mo
Sample size in a voluntary survey: the selection problem
Posting this under the heading it deserves: Sample size in a voluntary survey: the selection problem Everything below is what sits behind that. Posting the method first, because I know what the first three…
BVLDNLAIEK+1 5 12k 15mo
Absence of evidence and evidence of absence
Absence of evidence and evidence of absence Writing it up because I had to work it out twice and would rather nobody else did. Session topic: SURMOUNT-OSA ( N Engl J Med , 2024). Please read it before…
KRFDRNRMHF+16 20 3.9k 5mo
Second pass at: Designing a personal experiment that could change your mind
Second pass at: Designing a personal experiment that could change your mind Writing it up because I had to work it out twice and would rather nobody else did. Session topic: SURPASS-4 ( Lancet , 2021). Please…
JSJISTGBM+39 44 632 14mo
What pooling buys you and what it destroys
The question in the title: What pooling buys you and what it destroys I will give what I have already checked below so nobody repeats it. Comparing SURMOUNT-2 ( Lancet , 2023) with LEADER ( N Engl J Med ,…
MDEHDHPMNA+74 83 6.6k 8mo